Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Feb 4

PMID 32010144

Citations 31

Authors

E Pierik

Jelmer R Prins

Harry van Goor

Gustaaf A Dekker

Mohamed R Daha

Marc A J Seelen

Sicco A Scherjon

Affiliations

Soon will be listed here.

Abstract

Preeclampsia is one of the leading causes of maternal and neonatal mortality and morbidity worldwide, affecting 2-8% of all pregnancies. Studies suggest a link between complement activation and preeclampsia. The complement system plays an essential role in the innate immunity, leading to opsonization, inflammation, and elimination of potential pathogens. The complement system also provides a link between innate and adaptive immunity and clearance of immune complexes and apoptotic cells. During pregnancy there is increased activity of the complement system systemically. However, locally at the placenta, complement inhibition is crucial for the maintenance of a normal pregnancy. Inappropriate or excessive activation of the complement system at the placenta is likely involved in placental dysfunction, and is in turn associated with pregnancy complications like preeclampsia. Therefore, modulation of the complement system could be a potential therapeutic target to prevent pregnancy complications such as preeclampsia. This review, based on a systematic literature search, gives an overview of the complement system and its activation locally in the placenta and systemically during healthy pregnancies and during complicated pregnancies, with a focus on preeclampsia. Furthermore, this review describes results of animal and human studies with a focus on the complement system in pregnancy, and the role of the complement system in placental dysfunction. Various clinical and animal studies provide evidence that dysregulation of the complement system is associated with placental dysfunction and therefore with preeclampsia. Several drugs are used for prevention and treatment of preeclampsia in humans and animal models, and some of these drugs work through complement modulation. Therefore, this review further discusses these studies examining pharmaceutical interventions as treatment for preeclampsia. These observations will help direct research to generate new target options for prevention and treatment of preeclampsia, which include direct and indirect modulation of the complement system.

Citing Articles

Exosomal-complement system activation in preeclampsia.

David M, Maharaj N, Krishnan A J Obstet Gynaecol Res. 2025; 51(3):e16255.

PMID: 40070019 PMC: 11897585. DOI: 10.1111/jog.16255.

Prediction Models for Late-Onset Preeclampsia: A Study Based on Logistic Regression, Support Vector Machine, and Extreme Gradient Boosting Models.

Zhang Y, Gu X, Yang N, Xue Y, Ma L, Wang Y Biomedicines. 2025; 13(2).

PMID: 40002760 PMC: 11853338. DOI: 10.3390/biomedicines13020347.

Complement Factor B Deficiency Is Dispensable for Female Fertility but Affects Microbiome Diversity and Complement Activity.

Sunamoto M, Morohoshi K, Sato B, Mihashi R, Inui M, Yamada M Int J Mol Sci. 2025; 26(3).

PMID: 39941161 PMC: 11818189. DOI: 10.3390/ijms26031393.

Placental lesions in systemic lupus erythematosus pregnancies associated with small for gestational age infants.

Dhital R, Jacobs M, Smith C, Parast M Rheumatology (Oxford). 2024; 63(11):3006-3014.

PMID: 39196708 PMC: 11534143. DOI: 10.1093/rheumatology/keae454.

Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities.

Balduit A, Agostinis C, Mangogna A, Zito G, Stampalija T, Ricci G Front Immunol. 2024; 15:1419540.

PMID: 38983853 PMC: 11232388. DOI: 10.3389/fimmu.2024.1419540.

References

Penning M, Chua J, van Kooten C, Zandbergen M, Buurma A, Schutte J . Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia. Hypertension. 2015; 66(1):117-25. PMC: 4465860. DOI: 10.1161/HYPERTENSIONAHA.115.05484. View

Lashley L, Buurma A, Swings G, Eikmans M, Anholts J, Bakker J . Preeclampsia in autologous and oocyte donation pregnancy: is there a different pathophysiology?. J Reprod Immunol. 2015; 109:17-23. DOI: 10.1016/j.jri.2015.03.004. View

Hossain N, Schatz F, Paidas M . Heparin and maternal fetal interface: why should it work to prevent pregnancy complications?. Thromb Res. 2009; 124(6):653-5. DOI: 10.1016/j.thromres.2009.08.001. View

Gonzalez J, Pedroni S, Girardi G . Statins prevent cervical remodeling, myometrial contractions and preterm labor through a mechanism that involves hemoxygenase-1 and complement inhibition. Mol Hum Reprod. 2014; 20(6):579-89. DOI: 10.1093/molehr/gau019. View

Robertson S, Green E, Care A, Moldenhauer L, Prins J, Hull M . Therapeutic Potential of Regulatory T Cells in Preeclampsia-Opportunities and Challenges. Front Immunol. 2019; 10:478. PMC: 6448013. DOI: 10.3389/fimmu.2019.00478. View

Lillegard K, Loeks-Johnson A, Opacich J, Peterson J, Bauer A, Elmquist B . Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats. J Pharmacol Exp Ther. 2014; 351(2):344-51. PMC: 4201271. DOI: 10.1124/jpet.114.218123. View

Petitbarat M, Durigutto P, Macor P, Bulla R, Palmioli A, Bernardi A . Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. J Immunol. 2015; 195(12):5602-7. DOI: 10.4049/jimmunol.1501361. View

Sones J, Cha J, Woods A, Bartos A, Heyward C, Lob H . Decidual Cox2 inhibition improves fetal and maternal outcomes in a preeclampsia-like mouse model. JCI Insight. 2016; 1(3). PMC: 4855694. DOI: 10.1172/jci.insight.75351. View

Gelber S, Brent E, Redecha P, Perino G, Tomlinson S, Davisson R . Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency. J Immunol. 2015; 195(3):1129-38. PMC: 4506873. DOI: 10.4049/jimmunol.1402220. View

10.

Qing X, Redecha P, Burmeister M, Tomlinson S, DAgati V, Davisson R . Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2010; 79(3):331-9. DOI: 10.1038/ki.2010.393. View

11.

Gibson C, MacLennan A, Haan E, Priest K, Dekker G . Fetal MBL2 haplotypes combined with viral exposure are associated with adverse pregnancy outcomes. J Matern Fetal Neonatal Med. 2010; 24(6):847-54. DOI: 10.3109/14767058.2010.531324. View

12.

Ma Y, Kong L, Ge Q, Lu Y, Hong M, Zhang Y . Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. 2017; 22(2):1034-1046. PMC: 5783881. DOI: 10.1111/jcmm.13466. View

13.

Sarween N, Drayson M, Hodson J, Knox E, Plant T, Day C . Humoral immunity in late-onset Pre-eclampsia and linkage with angiogenic and inflammatory markers. Am J Reprod Immunol. 2018; 80(5):e13041. DOI: 10.1111/aji.13041. View

14.

Rolnik D, Wright D, Poon L, OGorman N, Syngelaki A, de Paco Matallana C . Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017; 377(7):613-622. DOI: 10.1056/NEJMoa1704559. View

15.

Tedesco F, Radillo O, Candussi G, Nazzaro A, Mollnes T, Pecorari D . Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol. 1990; 80(2):236-40. PMC: 1535286. DOI: 10.1111/j.1365-2249.1990.tb05240.x. View

16.

Wang C, Yim K, Poon T, Choy K, Chu C, Lui W . Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem. 2007; 53(1):42-52. DOI: 10.1373/clinchem.2007.074401. View

17.

Hering L, Herse F, Verlohren S, Park J, Wellner M, Qadri F . Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension. 2008; 51(2):554-9. DOI: 10.1161/HYPERTENSIONAHA.107.102905. View

18.

Cohen D, Buurma A, Goemaere N, Girardi G, le Cessie S, Scherjon S . Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol. 2011; 225(4):502-11. DOI: 10.1002/path.2893. View

19.

Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G . Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016; 126(8):2933-40. PMC: 4966313. DOI: 10.1172/JCI86957. View

20.

Roberge S, Bujold E, Nicolaides K . Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2017; 218(3):287-293.e1. DOI: 10.1016/j.ajog.2017.11.561. View